Krystal Biotech Q2 EPS $(1.25) Misses $(0.74) Estimate; Q2 Cash, Cash Equivalents And Investments Of $505.9M
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech reported Q2 losses of $(1.25) per share, missing the analyst consensus estimate of $(0.74) by 68.92%. This represents a 13.64% decrease over losses from the same period last year. The company also reported Q2 cash, cash equivalents and investments of $505.9M.
August 07, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Krystal Biotech's Q2 earnings missed analyst estimates by a significant margin, which could negatively impact investor sentiment.
Krystal Biotech's Q2 earnings missed analyst estimates by a significant margin. This could lead to a decrease in investor confidence and potentially a drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100